Bruker (NASDAQ:BRKR) Price Target Cut to $75.00 by Analysts at Wells Fargo & Company

Bruker (NASDAQ:BRKR) had its price target lowered by Wells Fargo & Company from $78.00 to $75.00 in a research note published on Wednesday, Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the company. TD Cowen dropped their price objective on Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Wednesday, August 7th. The Goldman Sachs Group lowered their price target on shares of Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Citigroup decreased their target price on shares of Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th. Finally, Barclays cut their price target on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $79.36.

Bruker Stock Performance

BRKR stock opened at $59.34 on Wednesday. Bruker has a 1-year low of $54.55 and a 1-year high of $94.86. The business has a 50-day moving average price of $63.97 and a 200 day moving average price of $66.51. The company has a market capitalization of $8.98 billion, a P/E ratio of 24.47, a PEG ratio of 2.32 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. Bruker’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.74 earnings per share. As a group, equities research analysts forecast that Bruker will post 2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Bruker

Large investors have recently made changes to their positions in the stock. First Horizon Advisors Inc. lifted its position in Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after acquiring an additional 218 shares during the period. Covestor Ltd raised its stake in shares of Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after purchasing an additional 210 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd purchased a new stake in Bruker in the second quarter valued at approximately $52,000. Finally, GAMMA Investing LLC increased its holdings in Bruker by 81.0% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.